Skip to main content

30-06-2016 | Multiple myeloma | Article

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma

Journal of Hematology & Oncology

Authors: Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang

Publisher: BioMed Central


Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM.

Please log in to get access to this content

Related topics

Image Credits